/
/
Sanofi Teams with Eureka Therapeutics and MSK on GPR5CD Non-CAR Myeloma Treatment
Sanofi Teams with Eureka Therapeutics and MSK on GPR5CD Non-CAR Myeloma Treatment image
Sanofi Teams with Eureka Therapeutics and MSK on GPR5CD Non-CAR Myeloma Treatment
Posted Jul 07, 2021

Sanofi Genzyme has signed a license agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center for the non-CAR use of a new treatment targeting GPRC5D. As you may know, GPRC5D is a new target being developed for CAR T treatment by Janssen Oncology. This new agreement allows the development of non-CAR myeloma treatments targeting GPRC5D in the joint venture. This could include, for example, the development of a bispecific antibody or monoclonal antibody that targets GPRC5D. 

The GPRC5D binding domain was discovered using Eureka's proprietary discover platform called E-ALPHA.® Dr. Eric L. Smith, myeloma physician-scientist and inventor on the patents said:

“GPRC5D is a novel target that has emerged as a promising option for the treatment of multiple myeloma, particularly for patients who have relapsed from other therapies.” 

 

Under the terms of the agreement, Sanofi has exclusive rights to the GPRC5D binder for non-CAR use. Eureka and MSK are eligible to receive an upfront payment and potential regulatory and sales milestone payments. Eureka and MSK are also eligible to receive tiered royalties on net sales.

Eureka Therapeutics is a California-based biotechnology company focused on developing new T cell therapies for cancer patients. They have treatments for solid tumor and blood cancers. 

For myeloma patients who are relapsing after BCMA directed treatments, the new GPRC5D target presents another welcome option. It will be interesting to see this target develop in myeloma care as new treatment approaches (both CAR T and non-CAR) are tested in clinical trials. 

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811